Evidence-based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis.

Recurrent vulvovaginal candidiasis (RVVC) is a subtype of vulvovaginal candidiasis, with debilitating effects on physical and emotional well-being affecting up to 10% of Australian women. Current evidence suggests that the induction and maintenance approach for RVVC is not particularly effective with post-treatment relapse rates as high as 57%. Frequently accessed Australasian RVVC prescribing resources and guidelines were examined showing a variety of adaptations of current evidence-based induction and maintenance therapies, making it difficult to select best treatment in clinical practice. The ways to introduce more clarity and consistency into these guidelines are outlined. © 2021 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

Citation

Moira Bradfield Strydom, Ramesh Lahiru Walpola, Sohil Khan, Robert S Ware, Evelin Tiralongo. Evidence-based update on Australasian pharmaceutical prescribing approaches for recurrent vulvovaginal candidiasis. The Australian & New Zealand journal of obstetrics & gynaecology. 2021 Aug;61(4):496-499

Mesh Tags

Substances

PMID: 34081319

search → result